PE144010: β-GalNAc-PEG4-Azide Pack Size:250 mg 5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosyl)onicacid]-(2→6)-(β-D-galactopyranosyl)-(1→4)-2-acetamido-2-deoxy-β-D-glucopyranoside

5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosyl)onicacid]-(2→6)-(β-D-galactopyranosyl)-(1→4)-2-acetamido-2-deoxy-β-D-glucopyranoside

1-[N-[2-[4-[[2-(2-Amino-4-thiazolyl)acetyl]amino]phenyl]ethyl]-N-[(2R)-2-hydroxy-2-phenylethyl]carbamate]- β-D-Glucopyranuronic Acid

/ Fmoc-Ser(Gal(Ac)4-β-D)-OH / N-α-Fmoc-O-β-(2

4-[6-Hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]benzoyl]benzo[b]thien-2-yl]phenyl-β-D-glucopyranosiduronic Acid

Fmoc-Ser(α-D-GalNAc(Ac)3)-OH

PE144010: β-GalNAc-PEG4-Azide Pack Size:250 mg 5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosyl)onicacid]-(2→6)-(β-D-galactopyranosyl)-(1→4)-2-acetamido-2-deoxy-β-D-glucopyranosideC16H30N4O9 422. 43 A D N acetylgalactosamine (GalNAc) ligand equipped with an azide handle through a hydrophilic PEG4 spacer. The terminal azide couples to alkynes via copper catalyzed azide alkyne cycloaddition (CuAAC) or to DBCO and related strained alkynes via copper free click chemistry, forming stable 1,2,3 triazole linkages. This compound enables the construction of hepatocyte targeted therapeutics and research tools that exploit the